TNF-α Treatment of Blast-Induced Tinnitus

NCT ID: NCT04066348

Last Updated: 2025-06-27

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 88 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-07-01
• Study Completion Date: 2025-09-30

Brief Summary

The purpose of this multi-site research study is to determine if Etanercept, compared to a placebo, significantly reduces the severity of tinnitus (ringing in the ears) associated with history of blast and/or noise exposure or associated with Traumatic Brain Injury (TBI) and/or concussion. Individuals who qualify will be randomized into one of two groups: The group receiving the medication Etanercept or the group receiving a saline solution placebo.

Detailed Description

The primary objectives are to test if: 1) Etanercept significantly reduces tinnitus distress as measured by Tinnitus Functional Index (TFI); and 2) Etanercept improves hearing. In addition, the investigators will explore whether Etanercept treatment leads to sustained therapeutic effects over time;

The secondary objective is to test if: 1) Etanercept reduces tinnitus loudness measured by visual numeric scale (VNS) rating.

Conditions

Tinnitus, Noise Induced

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Etanercept Injection Group

Subjects will receive 2 X 25mg/ 1ml etanercept injection (experimental) weekly for 12 weeks.

Group Type: EXPERIMENTAL

Etanercept

Intervention Type: BIOLOGICAL

To treat blast or noise induced tinnitus

Placebo Injection Group

Subjects will receive 2 X 1ml saline injection (placebo) weekly for 12 weeks.

Group Type: PLACEBO_COMPARATOR

Saline

Intervention Type: OTHER

Placebo

Interventions

Etanercept

To treat blast or noise induced tinnitus

Intervention Type: BIOLOGICAL

Saline

Placebo

Intervention Type: OTHER

Other Intervention Names

Enbrel

Eligibility Criteria

Inclusion Criteria

1. Tinnitus of at least a moderate severity as defined by a score of ≥ 25 points or higher on the Tinnitus Functional Index (TFI) questionnaire associated with one or more of the following:

1. Blast- or noise exposure

2. Traumatic brain injury (TBI) and/or concussion diagnosed by a health care provider.

2. Able to provide written informed consent.

3. Age: Minimum 18 years of age at the time of enrollment.

4. Other concurrent treatments for tinnitus: A four-week washout from any other tinnitus treatment or management program is required prior to entering this study.

a) Hearing aids are permitted if the participant has been wearing them for at least 4 weeks.

5. Hearing function: All degrees of hearing function can be included, recognizing that individuals with profound, bilateral hearing loss will not be able to perform tinnitus evaluations and hearing tests but will be able to rate subjective tinnitus loudness, annoyance and impact on life. This is an important sub-population because of the challenges in treating them with acoustic therapy and the need for a medical intervention.

6. Additional tinnitus characteristics:

a) Tinnitus history: Onset associated with blast and/or noise exposure or associated with diagnosed TBI and/or concussion. Subjects will have blast exposure, noise exposure, traumatic brain injury (TBI), and/or concussion impact, defined as exposure/impact less than or longer than six months at time of enrollment.

i. Participants enrolled with tinnitus associated with TBI and/or concussion must have received a diagnosis of TBI and/or concussion by a health care provider.

b) Stability: Constant (not pulsatile or intermittent). c) Location of tinnitus perception: Unrestricted. Tinnitus may be unilateral, bilateral, or perceived in the head.

Exclusion Criteria

1. History or evidence of any of the following: Significant brain malformation; cerebral vascular events (such as strokes); neurodegenerative disorders affecting the brain, such as Parkinson's disease, ALS, or Huntington's disease; multiple sclerosis, Guillain-Barré syndrome, or any other disease involving demyelination disorder or any finding suggesting a demyelination disease or disorder; prior brain surgery.

a. The following surgical procedures are not exclusionary: Evacuation of subdural hematoma, insertion of intracranial pressure monitor device, craniectomy

2. Active malignant neoplasm such as lymphoma or solid tumors or history of malignant neoplasm, excluding successfully treated squamous cell carcinoma or basal carcinoma of the skin or cervical cancer.

3. Diagnosis of congestive heart failure.

4. History of diagnosed seizure disorder or epilepsy.

5. Diagnosis of myelodysplastic syndrome or aplastic anemia, white blood cell count < 4000, or platelet count < 150,000.

6. Subjects who currently have an active infection, including tuberculosis, HIV, hepatitis B, and/or chicken pox.

a. Patients with latent hepatitis B infection are also excluded from participation.

7. Scheduled to receive a live vaccine during study participation or received a live vaccine within 2 weeks prior to screening visit/procedures.

8. Diagnosis of an auto-immune disease that, in the opinion of the investigator, would cause a weakened immune system.

a) Autoimmune thyroid disease is not considered an exclusionary autoimmune disease for participation in this study.

9. Diabetes.

10. Ongoing treatment with or plans to begin taking any of the following contraindicated medications: Cyclophosphamide or sulfasalazine; abatacept, anakinra, or any other immunomodulatory biologic therapy; sulfonylureas, meglitinides, or insulin.

11. Subjects who cannot communicate reliably with research team members or who are not likely to be able to complete the requirements of the trial per the discretion of the investigator.

12. Subjects who have participated in a drug clinical trial within the last 30 days before the start of this one.

13. Pregnancy or planned pregnancy during the study.

14. Women who are lactating or are of child-bearing-age without use of contraception.

15. MMSE score < 24.

16. Clinically significant out of range laboratory values for protocol required laboratory tests as assessed by the investigator.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Miami

OTHER

Sponsor Role: collaborator

Michigan Ear Institute

UNKNOWN

Sponsor Role: collaborator

Wayne State University

OTHER

Sponsor Role: lead

Responsible Party

Dr. Jinsheng Zhang

Principle Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Jinsheng Zhang, Ph. D.

Role: PRINCIPAL_INVESTIGATOR

Wayne State University

Locations

Advent Health

Celebration, Florida, United States

Site Status: RECRUITING

University of Miami

Coral Gables, Florida, United States

Site Status: RECRUITING

Wayne State University

Detroit, Michigan, United States

Site Status: RECRUITING

Michigan Ear Institute

Farmington Hills, Michigan, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Jamal Chehab

Role: CONTACT

tinnitustrial@wayne.edu

313-577-5495

Facility Contacts

Jamal Chehab, RN

Role: primary

tinnitustrial@wayne.edu

Role: primary

tinnitustrial@wayne.edu

Role: primary

tinnitustrial@wayne.edu

Role: primary

tinnitustrial@wayne.edu

References

Meikle MB, Henry JA, Griest SE, Stewart BJ, Abrams HB, McArdle R, Myers PJ, Newman CW, Sandridge S, Turk DC, Folmer RL, Frederick EJ, House JW, Jacobson GP, Kinney SE, Martin WH, Nagler SM, Reich GE, Searchfield G, Sweetow R, Vernon JA. The tinnitus functional index: development of a new clinical measure for chronic, intrusive tinnitus. Ear Hear. 2012 Mar-Apr;33(2):153-76. doi: 10.1097/AUD.0b013e31822f67c0.

Reference Type: BACKGROUND

PMID: 22156949 (View on PubMed)

Lew HL, Jerger JF, Guillory SB, Henry JA. Auditory dysfunction in traumatic brain injury. J Rehabil Res Dev. 2007;44(7):921-8. doi: 10.1682/jrrd.2007.09.0140.

Reference Type: BACKGROUND

PMID: 18075949 (View on PubMed)

VBA. VA Annual Benefits Report: Fiscal Year 2012. In: VA US, ed. 810 Vermont Avenue N. W. , Washington, D.C., 20420: Veterans Benefits Administration, 2013:82.

Reference Type: BACKGROUND

Hesser H, Westin V, Hayes SC, Andersson G. Clients' in-session acceptance and cognitive defusion behaviors in acceptance-based treatment of tinnitus distress. Behav Res Ther. 2009 Jun;47(6):523-8. doi: 10.1016/j.brat.2009.02.002. Epub 2009 Feb 10.

Reference Type: BACKGROUND

PMID: 19268281 (View on PubMed)

Crocetti A, Forti S, Ambrosetti U, Bo LD. Questionnaires to evaluate anxiety and depressive levels in tinnitus patients. Otolaryngol Head Neck Surg. 2009 Mar;140(3):403-5. doi: 10.1016/j.otohns.2008.11.036.

Reference Type: BACKGROUND

PMID: 19248952 (View on PubMed)

Hasson D, Theorell T, Wallen MB, Leineweber C, Canlon B. Stress and prevalence of hearing problems in the Swedish working population. BMC Public Health. 2011 Feb 23;11:130. doi: 10.1186/1471-2458-11-130.

Reference Type: BACKGROUND

PMID: 21345187 (View on PubMed)

Hebert S, Fullum S, Carrier J. Polysomnographic and quantitative electroencephalographic correlates of subjective sleep complaints in chronic tinnitus. J Sleep Res. 2011 Mar;20(1 Pt 1):38-44. doi: 10.1111/j.1365-2869.2010.00860.x.

Reference Type: BACKGROUND

PMID: 20561177 (View on PubMed)

Stevens C, Walker G, Boyer M, Gallagher M. Severe tinnitus and its effect on selective and divided attention. Int J Audiol. 2007 May;46(5):208-16. doi: 10.1080/14992020601102329.

Reference Type: BACKGROUND

PMID: 17487668 (View on PubMed)

Rossiter S, Stevens C, Walker G. Tinnitus and its effect on working memory and attention. J Speech Lang Hear Res. 2006 Feb;49(1):150-60. doi: 10.1044/1092-4388(2006/012).

Reference Type: BACKGROUND

PMID: 16533080 (View on PubMed)

Namas R, Ghuma A, Hermus L, Zamora R, Okonkwo DO, Billiar TR, Vodovotz Y. The acute inflammatory response in trauma / hemorrhage and traumatic brain injury: current state and emerging prospects. Libyan J Med. 2009 Sep 1;4(3):97-103. doi: 10.4176/090325.

Reference Type: BACKGROUND

PMID: 21483522 (View on PubMed)

Eyre H, Baune BT. Neuroplastic changes in depression: a role for the immune system. Psychoneuroendocrinology. 2012 Sep;37(9):1397-416. doi: 10.1016/j.psyneuen.2012.03.019. Epub 2012 Apr 21.

Reference Type: BACKGROUND

PMID: 22525700 (View on PubMed)

Beattie EC, Stellwagen D, Morishita W, Bresnahan JC, Ha BK, Von Zastrow M, Beattie MS, Malenka RC. Control of synaptic strength by glial TNFalpha. Science. 2002 Mar 22;295(5563):2282-5. doi: 10.1126/science.1067859.

Reference Type: BACKGROUND

PMID: 11910117 (View on PubMed)

Steinmetz CC, Turrigiano GG. Tumor necrosis factor-alpha signaling maintains the ability of cortical synapses to express synaptic scaling. J Neurosci. 2010 Nov 3;30(44):14685-90. doi: 10.1523/JNEUROSCI.2210-10.2010.

Reference Type: BACKGROUND

PMID: 21048125 (View on PubMed)

Stellwagen D, Malenka RC. Synaptic scaling mediated by glial TNF-alpha. Nature. 2006 Apr 20;440(7087):1054-9. doi: 10.1038/nature04671. Epub 2006 Mar 19.

Reference Type: BACKGROUND

PMID: 16547515 (View on PubMed)

Schaette R, Kempter R. Computational models of neurophysiological correlates of tinnitus. Front Syst Neurosci. 2012 May 8;6:34. doi: 10.3389/fnsys.2012.00034. eCollection 2012.

Reference Type: BACKGROUND

PMID: 22586377 (View on PubMed)

Yang S, Bao S. Homeostatic mechanisms and treatment of tinnitus. Restor Neurol Neurosci. 2013;31(2):99-108. doi: 10.3233/RNN-120248.

Reference Type: BACKGROUND

PMID: 23435453 (View on PubMed)

Yang S, Weiner BD, Zhang LS, Cho SJ, Bao S. Homeostatic plasticity drives tinnitus perception in an animal model. Proc Natl Acad Sci U S A. 2011 Sep 6;108(36):14974-9. doi: 10.1073/pnas.1107998108. Epub 2011 Sep 6.

Reference Type: BACKGROUND

PMID: 21896771 (View on PubMed)

Weinberg MS, Blake BL, McCown TJ. Opposing actions of hippocampus TNFalpha receptors on limbic seizure susceptibility. Exp Neurol. 2013 Sep;247:429-37. doi: 10.1016/j.expneurol.2013.01.011. Epub 2013 Jan 16.

Reference Type: BACKGROUND

PMID: 23333565 (View on PubMed)

Kaneko M, Stellwagen D, Malenka RC, Stryker MP. Tumor necrosis factor-alpha mediates one component of competitive, experience-dependent plasticity in developing visual cortex. Neuron. 2008 Jun 12;58(5):673-80. doi: 10.1016/j.neuron.2008.04.023.

Reference Type: BACKGROUND

PMID: 18549780 (View on PubMed)

Stellwagen D, Beattie EC, Seo JY, Malenka RC. Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-alpha. J Neurosci. 2005 Mar 23;25(12):3219-28. doi: 10.1523/JNEUROSCI.4486-04.2005.

Reference Type: BACKGROUND

PMID: 15788779 (View on PubMed)

Ogoshi F, Yin HZ, Kuppumbatti Y, Song B, Amindari S, Weiss JH. Tumor necrosis-factor-alpha (TNF-alpha) induces rapid insertion of Ca2+-permeable alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA)/kainate (Ca-A/K) channels in a subset of hippocampal pyramidal neurons. Exp Neurol. 2005 Jun;193(2):384-93. doi: 10.1016/j.expneurol.2004.12.026.

Reference Type: BACKGROUND

PMID: 15869941 (View on PubMed)

Llano DA, Turner J, Caspary DM. Diminished cortical inhibition in an aging mouse model of chronic tinnitus. J Neurosci. 2012 Nov 14;32(46):16141-8. doi: 10.1523/JNEUROSCI.2499-12.2012.

Reference Type: BACKGROUND

PMID: 23152598 (View on PubMed)

Middleton JW, Kiritani T, Pedersen C, Turner JG, Shepherd GM, Tzounopoulos T. Mice with behavioral evidence of tinnitus exhibit dorsal cochlear nucleus hyperactivity because of decreased GABAergic inhibition. Proc Natl Acad Sci U S A. 2011 May 3;108(18):7601-6. doi: 10.1073/pnas.1100223108. Epub 2011 Apr 18.

Reference Type: BACKGROUND

PMID: 21502491 (View on PubMed)

Brozoski T, Odintsov B, Bauer C. Gamma-aminobutyric acid and glutamic acid levels in the auditory pathway of rats with chronic tinnitus: a direct determination using high resolution point-resolved proton magnetic resonance spectroscopy (H-MRS). Front Syst Neurosci. 2012 Feb 24;6:9. doi: 10.3389/fnsys.2012.00009. eCollection 2012.

Reference Type: BACKGROUND

PMID: 22383901 (View on PubMed)

Isaacson JE, Moyer MT, Schuler HG, Blackall GF. Clinical associations between tinnitus and chronic pain. Otolaryngol Head Neck Surg. 2003 May;128(5):706-10. doi: 10.1016/S0194-59980300227-4.

Reference Type: BACKGROUND

PMID: 12748565 (View on PubMed)

Moller AR. Similarities between chronic pain and tinnitus. Am J Otol. 1997 Sep;18(5):577-85.

Reference Type: BACKGROUND

PMID: 9303153 (View on PubMed)

Tonndorf J. The analogy between tinnitus and pain: a suggestion for a physiological basis of chronic tinnitus. Hear Res. 1987;28(2-3):271-5. doi: 10.1016/0378-5955(87)90054-2.

Reference Type: BACKGROUND

PMID: 2820913 (View on PubMed)

De Ridder D, Elgoyhen AB, Romo R, Langguth B. Phantom percepts: tinnitus and pain as persisting aversive memory networks. Proc Natl Acad Sci U S A. 2011 May 17;108(20):8075-80. doi: 10.1073/pnas.1018466108. Epub 2011 Apr 18.

Reference Type: BACKGROUND

PMID: 21502503 (View on PubMed)

Ignatowski TA, Covey WC, Knight PR, Severin CM, Nickola TJ, Spengler RN. Brain-derived TNFalpha mediates neuropathic pain. Brain Res. 1999 Sep 11;841(1-2):70-7. doi: 10.1016/s0006-8993(99)01782-5.

Reference Type: BACKGROUND

PMID: 10546989 (View on PubMed)

Covey WC, Ignatowski TA, Knight PR, Spengler RN. Brain-derived TNFalpha: involvement in neuroplastic changes implicated in the conscious perception of persistent pain. Brain Res. 2000 Mar 17;859(1):113-22. doi: 10.1016/s0006-8993(00)01965-x.

Reference Type: BACKGROUND

PMID: 10720620 (View on PubMed)

Hess A, Axmann R, Rech J, Finzel S, Heindl C, Kreitz S, Sergeeva M, Saake M, Garcia M, Kollias G, Straub RH, Sporns O, Doerfler A, Brune K, Schett G. Blockade of TNF-alpha rapidly inhibits pain responses in the central nervous system. Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3731-6. doi: 10.1073/pnas.1011774108. Epub 2011 Jan 18.

Reference Type: BACKGROUND

PMID: 21245297 (View on PubMed)

Widomski D, Fretland DJ, Gasiecki AF, Collins PW. The prostaglandin analogs, misoprostol and SC-46275, potently inhibit cytokine release from activated human monocytes. Immunopharmacol Immunotoxicol. 1997 May;19(2):165-74. doi: 10.3109/08923979709007656.

Reference Type: BACKGROUND

PMID: 9130003 (View on PubMed)

Briner W, House J, O'Leary M. Synthetic prostaglandin E1 misoprostol as a treatment for tinnitus. Arch Otolaryngol Head Neck Surg. 1993 Jun;119(6):652-4. doi: 10.1001/archotol.1993.01880180068013.

Reference Type: BACKGROUND

PMID: 8499097 (View on PubMed)

Akkuzu B, Yilmaz I, Cakmak O, Ozluoglu LN. Efficacy of misoprostol in the treatment of tinnitus in patients with diabetes and/or hypertension. Auris Nasus Larynx. 2004 Sep;31(3):226-32. doi: 10.1016/j.anl.2004.03.005.

Reference Type: BACKGROUND

PMID: 15364356 (View on PubMed)

Page TH, Turner JJ, Brown AC, Timms EM, Inglis JJ, Brennan FM, Foxwell BM, Ray KP, Feldmann M. Nonsteroidal anti-inflammatory drugs increase TNF production in rheumatoid synovial membrane cultures and whole blood. J Immunol. 2010 Sep 15;185(6):3694-701. doi: 10.4049/jimmunol.1000906. Epub 2010 Aug 16.

Reference Type: BACKGROUND

PMID: 20713883 (View on PubMed)

Hwang JH, Chen JC, Yang SY, Wang MF, Chan YC. Expression of tumor necrosis factor-alpha and interleukin-1beta genes in the cochlea and inferior colliculus in salicylate-induced tinnitus. J Neuroinflammation. 2011 Apr 9;8:30. doi: 10.1186/1742-2094-8-30.

Reference Type: BACKGROUND

PMID: 21477330 (View on PubMed)

Wang HT, Luo B, Zhou KQ, Xu TL, Chen L. Sodium salicylate reduces inhibitory postsynaptic currents in neurons of rat auditory cortex. Hear Res. 2006 May;215(1-2):77-83. doi: 10.1016/j.heares.2006.03.004. Epub 2006 Apr 24.

Reference Type: BACKGROUND

PMID: 16632286 (View on PubMed)

Satoh H, Firestein GS, Billings PB, Harris JP, Keithley EM. Tumor necrosis factor-alpha, an initiator, and etanercept, an inhibitor of cochlear inflammation. Laryngoscope. 2002 Sep;112(9):1627-34. doi: 10.1097/00005537-200209000-00019.

Reference Type: BACKGROUND

PMID: 12352677 (View on PubMed)

Wang X, Truong T, Billings PB, Harris JP, Keithley EM. Blockage of immune-mediated inner ear damage by etanercept. Otol Neurotol. 2003 Jan;24(1):52-7. doi: 10.1097/00129492-200301000-00012.

Reference Type: BACKGROUND

PMID: 12544029 (View on PubMed)

Matteson EL, Choi HK, Poe DS, Wise C, Lowe VJ, McDonald TJ, Rahman MU. Etanercept therapy for immune-mediated cochleovestibular disorders: a multi-center, open-label, pilot study. Arthritis Rheum. 2005 Jun 15;53(3):337-42. doi: 10.1002/art.21179.

Reference Type: BACKGROUND

PMID: 15934127 (View on PubMed)

Rahman MU, Poe DS, Choi HK. Etanercept therapy for immune-mediated cochleovestibular disorders: preliminary results in a pilot study. Otol Neurotol. 2001 Sep;22(5):619-24. doi: 10.1097/00129492-200109000-00010.

Reference Type: BACKGROUND

PMID: 11568668 (View on PubMed)

Van Wijk F, Staecker H, Keithley E, Lefebvre PP. Local perfusion of the tumor necrosis factor alpha blocker infliximab to the inner ear improves autoimmune neurosensory hearing loss. Audiol Neurootol. 2006;11(6):357-65. doi: 10.1159/000095897. Epub 2006 Sep 21.

Reference Type: BACKGROUND

PMID: 16988499 (View on PubMed)

Scherer EQ, Yang J, Canis M, Reimann K, Ivanov K, Diehl CD, Backx PH, Wier WG, Strieth S, Wangemann P, Voigtlaender-Bolz J, Lidington D, Bolz SS. Tumor necrosis factor-alpha enhances microvascular tone and reduces blood flow in the cochlea via enhanced sphingosine-1-phosphate signaling. Stroke. 2010 Nov;41(11):2618-24. doi: 10.1161/STROKEAHA.110.593327. Epub 2010 Oct 7.

Reference Type: BACKGROUND

PMID: 20930159 (View on PubMed)

Hiller W, Goebel G. A psychometric study of complaints in chronic tinnitus. J Psychosom Res. 1992 May;36(4):337-48. doi: 10.1016/0022-3999(92)90070-i.

Reference Type: BACKGROUND

PMID: 1593509 (View on PubMed)

Falkenberg ES, Wie OB. Anxiety and depression in tinnitus patients: 5-year follow-up assessment after completion of habituation therapy. Int J Otolaryngol. 2012;2012:375460. doi: 10.1155/2012/375460. Epub 2012 Mar 28.

Reference Type: BACKGROUND

PMID: 22536254 (View on PubMed)

Halford JB, Anderson SD. Anxiety and depression in tinnitus sufferers. J Psychosom Res. 1991;35(4-5):383-90. doi: 10.1016/0022-3999(91)90033-k.

Reference Type: BACKGROUND

PMID: 1920169 (View on PubMed)

Harrop-Griffiths J, Katon W, Dobie R, Sakai C, Russo J. Chronic tinnitus: association with psychiatric diagnoses. J Psychosom Res. 1987;31(5):613-21. doi: 10.1016/0022-3999(87)90040-7.

Reference Type: BACKGROUND

PMID: 3430424 (View on PubMed)

Henry JL, Wilson PH. Coping with Tinnitus: Two Studies of Psychological and Audiological Characteristics of Patients with High and Low Tinnitus-Related Distress. Int Tinnitus J. 1995;1(2):85-92.

Reference Type: BACKGROUND

PMID: 10753328 (View on PubMed)

Seydel C, Haupt H, Olze H, Szczepek AJ, Mazurek B. Gender and chronic tinnitus: differences in tinnitus-related distress depend on age and duration of tinnitus. Ear Hear. 2013 Sep;34(5):661-72. doi: 10.1097/AUD.0b013e31828149f2.

Reference Type: BACKGROUND

PMID: 23439056 (View on PubMed)

Tyler RS, Gogel SA, Gehringer AK. Tinnitus activities treatment. Prog Brain Res. 2007;166:425-34. doi: 10.1016/S0079-6123(07)66041-5.

Reference Type: BACKGROUND

PMID: 17956807 (View on PubMed)

Tyler R, Ji H, Perreau A, Witt S, Noble W, Coelho C. Development and validation of the tinnitus primary function questionnaire. Am J Audiol. 2014 Sep;23(3):260-72. doi: 10.1044/2014_AJA-13-0014.

Reference Type: BACKGROUND

PMID: 24811293 (View on PubMed)

Scott B, Lindberg P, Melin L, Lyttkens L. Predictors of tinnitus discomfort, adaptation and subjective loudness. Br J Audiol. 1990 Feb;24(1):51-62. doi: 10.3109/03005369009077842.

Reference Type: BACKGROUND

PMID: 2317601 (View on PubMed)

Herbert TB, Cohen S. Stress and immunity in humans: a meta-analytic review. Psychosom Med. 1993 Jul-Aug;55(4):364-79. doi: 10.1097/00006842-199307000-00004.

Reference Type: BACKGROUND

PMID: 8416086 (View on PubMed)

Kiecolt-Glaser JK, Marucha PT, Malarkey WB, Mercado AM, Glaser R. Slowing of wound healing by psychological stress. Lancet. 1995 Nov 4;346(8984):1194-6. doi: 10.1016/s0140-6736(95)92899-5.

Reference Type: BACKGROUND

PMID: 7475659 (View on PubMed)

Huerta PT, Kowal C, DeGiorgio LA, Volpe BT, Diamond B. Immunity and behavior: antibodies alter emotion. Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):678-83. doi: 10.1073/pnas.0510055103. Epub 2006 Jan 4.

Reference Type: BACKGROUND

PMID: 16407105 (View on PubMed)

Andrews JA, Neises KD. Cells, biomarkers, and post-traumatic stress disorder: evidence for peripheral involvement in a central disease. J Neurochem. 2012 Jan;120(1):26-36. doi: 10.1111/j.1471-4159.2011.07545.x. Epub 2011 Nov 17.

Reference Type: BACKGROUND

PMID: 22017326 (View on PubMed)

Hansel A, Hong S, Camara RJ, von Kanel R. Inflammation as a psychophysiological biomarker in chronic psychosocial stress. Neurosci Biobehav Rev. 2010 Sep;35(1):115-21. doi: 10.1016/j.neubiorev.2009.12.012. Epub 2009 Dec 22.

Reference Type: BACKGROUND

PMID: 20026349 (View on PubMed)

Steptoe A, Hamer M, Chida Y. The effects of acute psychological stress on circulating inflammatory factors in humans: a review and meta-analysis. Brain Behav Immun. 2007 Oct;21(7):901-12. doi: 10.1016/j.bbi.2007.03.011. Epub 2007 May 1.

Reference Type: BACKGROUND

PMID: 17475444 (View on PubMed)

Bob P, Raboch J, Maes M, Susta M, Pavlat J, Jasova D, Vevera J, Uhrova J, Benakova H, Zima T. Depression, traumatic stress and interleukin-6. J Affect Disord. 2010 Jan;120(1-3):231-4. doi: 10.1016/j.jad.2009.03.017.

Reference Type: BACKGROUND

PMID: 19359044 (View on PubMed)

Szczepek AJ, Haupt H, Klapp BF, Olze H, Mazurek B. Biological correlates of tinnitus-related distress: an exploratory study. Hear Res. 2014 Dec;318:23-30. doi: 10.1016/j.heares.2014.10.007. Epub 2014 Oct 28.

Reference Type: BACKGROUND

PMID: 25445818 (View on PubMed)

Weber C, Arck P, Mazurek B, Klapp BF. Impact of a relaxation training on psychometric and immunologic parameters in tinnitus sufferers. J Psychosom Res. 2002 Jan;52(1):29-33. doi: 10.1016/s0022-3999(01)00281-1.

Reference Type: BACKGROUND

PMID: 11801262 (View on PubMed)

Arck PC, Rose M, Hertwig K, Hagen E, Hildebrandt M, Klapp BF. Stress and immune mediators in miscarriage. Hum Reprod. 2001 Jul;16(7):1505-11. doi: 10.1093/humrep/16.7.1505.

Reference Type: BACKGROUND

PMID: 11425839 (View on PubMed)

Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189-98. doi: 10.1016/0022-3956(75)90026-6. No abstract available.

Reference Type: BACKGROUND

PMID: 1202204 (View on PubMed)

Andersson G. Tinnitus loudness matchings in relation to annoyance and grading of severity. Auris Nasus Larynx. 2003 May;30(2):129-33. doi: 10.1016/s0385-8146(03)00008-7.

Reference Type: BACKGROUND

PMID: 12753982 (View on PubMed)

Andersson G, Lyttkens L, Larsen HC. Distinguishing levels of tinnitus distress. Clin Otolaryngol Allied Sci. 1999 Sep;24(5):404-10. doi: 10.1046/j.1365-2273.1999.00278.x.

Reference Type: BACKGROUND

PMID: 10542919 (View on PubMed)

Provided Documents

Document Type: Informed Consent Form

View Document

Other Identifiers

PR172190

Identifier Type: -

Identifier Source: org_study_id